CoChat

The Skp2 Pathway: A Critical Target for Cancer Therapy

Open access
Cai, Zhen, Moten, Asad, Peng, Danni, Hsu, Che-Chia, Pan, Bo-Syong, Manne, Rajeshkumar, Li, Hong-yu, Lin, Hui-Kuan · 2020 · Seminars in Cancer Biology
Cited by 186

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Strictly regulated protein degradation by ubiquitin-proteasome system (UPS) is essential for various cellular processes whose dysregulation is linked to serious diseases including cancer. Skp2, a well characterized component of Skp2-SCF E3 ligase complex, is able to conjugate both K48-linked ubiquitin chains and K63-linked ubiquitin chains on its diverse substrates, inducing proteasome mediated proteolysis or modulating the function of tagged substrates respectively. Overexpression of Skp2 is observed in various human cancers associated with poor survival and adverse therapeutic outcomes, which in turn suggests that Skp2 engages in tumorigenic activity. To that end, the oncogenic properties of Skp2 are demonstrated by various genetic mouse models, highlighting the potential of Skp2 as a target for tackling cancer. In this article, we will describe the downstream substrates of Skp2 as well as upstream regulators for Skp2-SCF complex activity. We will further summarize the comprehensive oncogenic functions of Skp2 while describing diverse strategies and therapeutic platforms currently available for developing Skp2 inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2020.01.013

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Metadata

Authors
Cai, Z., Moten, A., Peng, D., Hsu, C.-C., Pan, B.-S., Manne, R., Li, H.-Y., & Lin, H.-K.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2020-12
Volume
67
Issue
Pt 2
Pages
16-33
ISSN
1044-579X (ISSN-L)
OpenAlex
W3003982277
Cited by
186
References
27
FWCI
6.85
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Skp2 Pathway: A Critical Target for Cancer Therapy. https://app.cochat.ai/papers/10.1016/j.semcancer.2020.01.013
The paper
Cai, Z., Moten, A., Peng, D., Hsu, C.-C., Pan, B.-S., Manne, R., Li, H.-Y., & Lin, H.-K. (2020). The Skp2 Pathway: A Critical Target for Cancer Therapy. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2020.01.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.